文献速递眼底病与葡萄膜炎

抗结核治疗对潜伏性结核相关葡萄膜炎的影响

Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis.
PubMed 文献 · Am J Ophthalmol · 2018-03-29

这项回顾性队列研究纳入129例潜伏性结核相关葡萄膜炎患者(199只眼),其中89例(69%)接受抗结核治疗(ATT)。所有患者均接受局部和全身抗炎及免疫抑制治疗。ATT组眼复发率29.5%,未接受ATT组48.2%(OR 0.47,95%CI 0.29-0.77,P=.003);ATT组首次复发中位时间120个月,未治疗组51个月(P=.005)。结论认为ATT使葡萄膜炎复发风险减半并延迟首次复发。

要点

  • ATT组眼复发率29.5%,未接受ATT组48.2%(OR 0.47,95%CI 0.29-0.77,P=.003)。
  • ATT组首次复发估计中位时间120个月,未治疗组51个月(P=.005)。
  • 所有患者均接受局部和全身抗炎及免疫抑制治疗,BCVA平均变化4.5±1.4个字母,两组间无差异。

核心结论

  • 接受ATT使潜伏性结核相关葡萄膜炎患眼的复发风险减半,并延迟首次复发时间。

研究设计与样本

  • 回顾性队列研究,纳入129例潜伏性结核相关葡萄膜炎患者共199只眼,其中89例(69%)接受ATT,40例未接受。

主要发现

  • 治疗后BCVA平均变化4.5±1.4个字母,接受ATT与未接受ATT的眼之间无差异。
  • 68只眼(34.9%)出现葡萄膜炎复发,年复发率为0.64±0.08次。
  • 接受ATT的眼较未接受ATT的眼更少发生复发(29.5% vs 48.2%,OR 0.47,95%CI 0.29-0.77,P=.003)。
  • 接受ATT的眼首次复发估计中位时间为120个月,未治疗眼为51个月(P=.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the clinical features of patients with uveitis associated with latent tuberculosis (TB) and examine the effect of anti-TB treatment (ATT) on uveitis outcome. DESIGN: Retrospective cohort study. METHODS: One hundred ninety-nine eyes of 129 patients diagnosed with uveitis associated with latent TB were evaluated for recurrence of disease following treatment. Eighty-nine of the patients (69%) received ATT and information was gathered retrospectively regarding clinical outcome, vision, and treatment. Outcome measures included best-corrected visual acuity (BCVA) and rate of disease recurrence. RESULTS: This study included 89 patients (69%) who received ATT and 40 patients who did not. The uveitis was treated with local and systemic anti-inflammatory and immunosuppressive therapy in all patients. The mean change in BCVA following treatment was 4.5 ± 1.4 letters over the follow-up period, with no difference between eyes of patients receiving ATT and those who did not. Sixty-eight eyes (34.9%) had a recurrence of uveitis (0.64 ± 0.08 recurrences per year), with eyes of patients receiving ATT less likely to develop a recurrence compared to those not receiving ATT (29.5% vs 48.2%, odds ratio 0.47, 95% confidence interval 0.29-0.77, P = .003). Eyes treated with ATT recurred at an estimated median of 120 months, compared with 51 months in eyes with no treatment (P = .005). CONCLUSIONS: Treatment with ATT halved the risk of uveitis recurrence and delayed the onset of the first recurrence in eyes with uveitis associated with latent TB.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tomkins-Netzer O, Leong BCS, Zhang X, et al. Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis. Am J Ophthalmol. 2018. PMID: 29604284. doi:10.1016/j.ajo.2018.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。